select a format

Single User License
USD 125 INR 8099
Site License
USD 250 INR 16198
Corporate User License
USD 375 INR 24296

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Alnylam Pharmaceuticals Inc (ALNY)-Financial and Strategic SWOT Analysis Review

Alnylam Pharmaceuticals Inc (ALNY)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH66532FSA
  • |
  • Pages: 61
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Alnylam Pharmaceuticals Inc (ALNY)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease; and hepatic infectious disease. It also offers Alnylam 5x15 program for advancing genetically defined disease targets for the treatment of respiratory syncytial virus and liver cancer. Alnylam employs lipid nanoparticles for intravenous systemic delivery of sRNAi to right body organs and cells so that it could trigger the RNAi mechanism. The company works in partnership with Merck, Medtronic, Roche, Novartis, Biogen, Takeda, Cubist, GlaxoSmithKline, Ascletis, The Medicines Company, Kyowa Hakko Kirin, Monsanto, and Sanofi Genzyme for advancing its RNAi therapeutics. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Feb 08,2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity

Jan 03,2017: Alnylam Announces Management Change and Key Promotion

Dec 16,2016: Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy

Nov 02,2016: Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity

Sep 20,2016: Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Alnylam Pharmaceuticals Inc-Key Facts 6

Alnylam Pharmaceuticals Inc-Key Employees 7

Alnylam Pharmaceuticals Inc-Key Employee Biographies 9

Alnylam Pharmaceuticals Inc-Major Products and Services 10

Alnylam Pharmaceuticals Inc-Pharmaceutical Pipeline Products Data 11

Alnylam Pharmaceuticals Inc, Pipeline Products by Therapy Area 11

Alnylam Pharmaceuticals Inc, Pipeline Products by Development Phase 11

Alnylam Pharmaceuticals Inc-History 13

Alnylam Pharmaceuticals Inc-Company Statement 18

Alnylam Pharmaceuticals Inc-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Joint Venture 19

Section 2-Company Analysis 21

Alnylam Pharmaceuticals Inc-Business Description 21

Alnylam Pharmaceuticals Inc-Corporate Strategy 22

Alnylam Pharmaceuticals Inc-SWOT Analysis 23

SWOT Analysis-Overview 23

Alnylam Pharmaceuticals Inc-Strengths 23

Alnylam Pharmaceuticals Inc-Weaknesses 24

Alnylam Pharmaceuticals Inc-Opportunities 25

Alnylam Pharmaceuticals Inc-Threats 26

Alnylam Pharmaceuticals Inc-Key Competitors 27

Section 3-Company Financial Ratios 28

Financial Ratios-Capital Market Ratios 28

Financial Ratios-Annual Ratios 29

Performance Chart 31

Financial Performance 31

Financial Ratios-Interim Ratios 32

Financial Ratios-Ratio Charts 33

Section 4-Company's Lifesciences Financial Deals and Alliances 34

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 34

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 36

Alnylam Pharmaceuticals Inc, Recent Deals Summary 37

Section 5-Company's Recent Developments 38

Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 38

Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 41

Dec 16, 2016: Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy 42

Nov 02, 2016: Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity 44

Sep 20, 2016: Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK 47

Sep 19, 2016: Alnylam Expands and Strengthens Management Team as it Plans for Commercialization 48

Aug 04, 2016: Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress 49

Aug 04, 2016: Jacobs wins contract for new Alnylam Biopharmaceutical manufacturing facility 52

Jul 12, 2016: Alnylam to Host Third Annual RNAi Roundtable Webcast Series 53

May 02, 2016: Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress 54

Section 6-Appendix 57

Methodology 57

Ratio Definitions 57

About GlobalData 61

Contact Us 61

Disclaimer 61

List of Figures

Alnylam Pharmaceuticals Inc, Pipeline Products by Therapy Area 11

Alnylam Pharmaceuticals Inc, Pipeline Products by Development Phase 11

Alnylam Pharmaceuticals Inc, Performance Chart (2012-2016) 31

Alnylam Pharmaceuticals Inc, Ratio Charts 33

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 34

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 36

List of Tables

Alnylam Pharmaceuticals Inc, Key Facts 6

Alnylam Pharmaceuticals Inc, Key Employees 7

Alnylam Pharmaceuticals Inc, Key Employee Biographies 9

Alnylam Pharmaceuticals Inc, Major Products and Services 10

Alnylam Pharmaceuticals Inc, Number of Pipeline Products by Development Stage 12

Alnylam Pharmaceuticals Inc, History 13

Alnylam Pharmaceuticals Inc, Subsidiaries 19

Alnylam Pharmaceuticals Inc, Joint Venture 19

Alnylam Pharmaceuticals Inc, Key Competitors 27

Alnylam Pharmaceuticals Inc, Ratios based on current share price 28

Alnylam Pharmaceuticals Inc 29

Alnylam Pharmaceuticals Inc (Cont...1) 30

Alnylam Pharmaceuticals Inc, Interim Ratios 32

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 34

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 36

Alnylam Pharmaceuticals Inc, Recent Deals Summary 37

Currency Codes 57

Capital Market Ratios 57

Equity Ratios 58

Profitability Ratios 58

Cost Ratios 59

Liquidity Ratios 59

Leverage Ratios 60

Efficiency Ratios 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Valeant Pharmaceuticals International Inc Sylentis SAU Silence Therapeutics Plc Quark Pharmaceuticals Inc MyoKardia Inc Marina Biotech Inc Kyowa Hakko Kirin Pharma Inc Dicerna Pharmaceuticals Inc Calando Pharmaceuticals, Inc. (formerly Insert Therapeutics, Inc.) Arrowhead Pharmaceuticals Inc Arcturus Therapeutics Inc Arbutus Biopharma Corp

Alnylam Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com